My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by OncoNano Medicine, Inc.

OncoNano Medicine Announces Presentation at AACR-NIC-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine To Present a Trials in Progress Poster for ON-5001 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL-12 Program at AACR Annual Meeting 2024
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine to Present Late-Breaking Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Appoints Kartik Krishnan as Chief Executive Officer and Promotes Melissa Paoloni to Chief Operating Officer
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research & Development
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR Annual Meeting 2023
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine’s Pegsitacianine Granted Breakthrough Therapy Designation for Real-Time Surgical Imaging by the Food and Drug Administration
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces New Preclinical Data for ON-BOARD™ Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine to Present Data on Novel Development Candidates at the Society for Immunology of Cancer (SITC) Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine to Present at Cantor Fitzgerald Oncology & HemOnc Conference
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Oral Presentation of Phase 2 Study Data at the World Molecular Imaging Congress 2022
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces the Appointment of Elina Lavit as Vice President, Business Development
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Positive Preclinical Data for Tumor Specific Delivery with the ON-BOARD™ Platform at AACR 2022 Annual Meeting
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Appoints Brett Giroir, M.D., to Board of Directors
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Announces $18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas
From OncoNano Medicine, Inc.
Via Business Wire
Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR Virtual Conference on Tumor Immunology and Immunotherapy
From OncoNano Medicine, Inc.
Via Business Wire
OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy
From OncoNano Medicine, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.